Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Inclusion Criteria: measurable metastatic adenocarcinoma of the colon or rectum no prior systemic therapy for metastatic disease adjuvant therapy must have been completed >/=12 months prior to recurrence, prior radiotherapy permitted but must have been completed > 6 months prior to study entry must have tumor tissue available for EGFR and thymidine phosphorylase evaluation ECOG PS 0-1 age >/= 18 adequate organ function: WBC>/=3,000, ANC >/=1,500, platelets>/= 100,000, total bilirubin </= 1.5X ULN, AST&ALT </= 2.5X ULN, create clearance >/= 50mL/min negative pregnancy test w/in 72 hours of treatment for women of child bearing potential ability to understand and willing to sign written ICF able to swallow and absorb oral medication Exclusion Criteria: medical or psychiatric condition which would potentially pose risk to patient by participation (i.e. but not limited to:uncontrolled hypertension, MI w/in 6 months,CNS disease, pregnancy or nursing) history of neoplasm (other than non-metastatic skin cancer or carcinoma in situ of cervix) w/in 5 years surgical procedure (not including closed biopsy or access port placement), open biopsy, significant traumatic injury w/in 28 days of registration or anticipation of need for surgical procedure while on study, fine needle aspiration or core biopsy w/in 7 days of registration urine protein:creatinine ration >/=1.0 at screening evidence of bleeding diathesis or coagulopathy (in absence of anticoagulation) prior severe infusion reaction to MAB or allergic reaction to capecitabine or oxaliplatin underlying neuropathy >/= grade 2 TIA or CVA w/in 6 months